# US 2002/0176863 A1 · Antigen of hybrid M protein and carrier for group A streptococcal vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0176863 A1
- Document ID: US20020176863A1
- Status: Published application
- Kind: A1
- Application number: 10/141,627
- Filed: 2002-05-07
- Published: 2002-11-28
- Earliest claimed: 1992-09-16
- Assignees: The University of Tennessee Research Corporation
- Inventors: James B. Dale
- Web page: https://patentgrep.com/patent/US20020176863A1

## CPC

- A61K 39/092: {Streptococcus}
- C07K 14/245: Escherichia (G)
- C07K 14/315: from Streptococcus (G), e.g. Enterococci
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- Y10S 530/806: Antigenic peptides or proteins
- Y10S 530/807: Hapten conjugated with peptide or protein
- Y10S 530/825: Bacteria
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

Recombinant hybrid streptococcal M protein antigens are provided which elicit protective antibodies against Group A streptococci and prevent rheumatic fever. Recombinant hybrid genes which encode the antigen are provided. Vaccine compositions and methods of administering the compositions are provided to elicit immunity against Group A streptococci.

## Claims

### Claim 1

A recombinant hybrid Streptococcal M protein antigen, comprising a carrier fused to at least one amino-terminal peptide fragment of streptococcal M protein having an epitope that elicits opsonic antibodies to at least one group A streptococci serotype without eliciting cross-reactive antibodies to mammalian tissue antigens.

### Claim 2 (depends on 1)

The antigen of claim 1 wherein the amino-terminal peptide_fragment of streptococcal M protein contains 10 amino acids to 35 amino acids.

### Claim 3 (depends on 2)

The antigen of claim 2 wherein the amino-terminal peptide fragment of streptococcal M protein contains 15 amino acids.

### Claim 4 (depends on 1)

The antigen of claim 1 wherein the carrier elicits mucosal antibodies.

### Claim 5 (depends on 1)

The antigen of claim 1, wherein the carrier is free of an epitope that elicits antibodies to a serotype of streptococcal M protein.

### Claim 6 (depends on 5)

The antigen of claim 5 wherein the carrier is a B subunit of E. coli labile toxin.

### Claim 7 (depends on 5)

The antigen of claim 5 wherein the carrier has a C-repeat portion of a Streptococcal M protein.

### Claim 8 (depends on 5)

The antigen of claim 5, wherein the carrier is a carboxy-terminal portion of a Streptococcal M protein.

### Claim 9 (depends on 8)

The antigen of claim 8, wherein the carboxy-terminal portion is of M5.

### Claim 10 (depends on 5)

The antigen of claim 5, wherein the carrier is the carboxy-terminal portion of a surface protein from a Gram-positive cocci.

### Claim 11 (depends on 5)

The antigen of claim 5, wherein the carrier is selected from the group consisting of tetanus toxoid, diphtheria toxoid, bovine serum albumin, hen egg lysozyme, gelatin, bovine gamma globulin, B subunit of cholera toxin, B subunit of E. coli labile toxin and flagellin polymer.

### Claim 12 (depends on 1)

The antigen of claim 1 wherein the carrier and said at least one amino-terminal peptide fragment of streptococcal M protein are linked in tandem by a linker comprising amino acids.

### Claim 13 (depends on 12)

The antigen of claim 12, wherein the amino acids of the linker are encoded by a nucleotide sequence comprising a restriction enzyme site.

### Claim 14 (depends on 12)

The antigen of claim 12 wherein the linker ranges in size from 1 amino acid to 30 amino acids.

### Claim 15 (depends on 12)

The antigen of claim 12, wherein the linker ranges in size from 2 amino acids to 7 amino acids.

### Claim 16 (depends on 12)

The antigen of claim 12, wherein the linker comprises hydrophobic amino acids.

### Claim 17 (depends on 16)

The antigen of claim 16, wherein the hydrophobic amino acids are selected from the group consisting of tryptophan, alanine, leucine, isoleucine, valine, tyrosine, phenylalanine, proline, methionine and combinations thereof.

### Claim 18 (depends on 12)

The antigen of claim 12, wherein the linker is proline-rich.

### Claim 19 (depends on 16)

The antigen of claim 16, wherein the linker is selected from the group consisting of Ile-Pro-Gly, Pro-Gly-Asn-Pro-Ala-Val-Pro (SEQ ID NO: 15), and Asp-Pro-Arg-Val-Pro-Ser-Ser (SEQ ID NO: 16).

### Claim 20 (depends on 18)

The antigen of claim 18, wherein the linker has two or three prolines and two or three glycines.

### Claim 21 (depends on 12)

The antigen of claim 12, wherein the linker is His-Gly or Gly-Ser.

### Claim 22 (depends on 1)

The antigen of claim 1 wherein said serotype of Group A streptococcal M protein is at least one of serotype M 1, M3, M12, M18, or M 19.

### Claim 23 (depends on 12)

The antigen of claim 12 wherein said serotype of Group A streptococcal M protein is at least one of serotype M1, M3, M12, M18, or M19.

### Claim 24 (depends on 1)

The antigen of claim 1 wherein at least one serotype is from rheumatogenic streptococci.

### Claim 25 (depends on 12)

The antigen of claim 12 wherein at least one serotype is from rheumatogenic streptococci.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A composition, comprising a biologically acceptable diluent or adjuvant and the antigen according to any one of claims 1-25.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A cocktail composition, comprising at least two recombinant hybrid Streptococcal M protein antigens according to any one of claims 1-25.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A nucleic acid molecule comprising a nucleotide sequence encoding a recombinant hybrid Streptococcal M protein antigen according to any one of claims 1-25.

### Claim 29 (depends on 28)

A nucleic acid expression construct comprising the nucleic acid molecule according to claim 28, wherein a host cell containing the nucleic acid expression construct can express the recombinant hybrid Streptococcal M protein antigen encoded by the nucleic acid molecule.

### Claim 30 (depends on 29)

A host cell comprising a nucleic acid expression construct according to claim 29.

### Claim 31 (depends on 30)

A method of producing a recombinant hybrid Streptococcal M protein antigen, comprising growing a host cell according to claim 30 under conditions that allow expression of a recombinant hybrid Streptococcal M protein antigen, and isolating the expressed recombinant hybrid Streptococcal M protein antigen.

### Claim 32 (depends on 31)

A recombinant hybrid Streptococcal M protein antigen produced by the method of claim 31.

### Claim 33 (depends on 28)

A method for eliciting opsonic antibodies to at least one group A streptococci without eliciting cross-reactive antibodies to mammalian tissue antigens, comprising administering to a patient in need thereof an effective amount of a composition comprising a biologically acceptable diluent and a non-virulent, live host cell containing a nucleic acid expression construct comprising the nucleic acid molecule according to claim 28, wherein a host cell containing the nucleic acid expression construct can express the recombinant hybrid Streptococcal M protein antigen encoded by the nucleic acid molecule.

### Claim 34 (depends on 33)

The method of claim 33 wherein the expressed recombinant hybrid Streptococcal M protein antigen is compartmentalized intracellularly, wherein release of the antigen from a host cell elicits opsonic antibodies.

### Claim 35 (depends on 33)

The method of claim 33 wherein the carrier is the carboxy-terminal portion of a surface of a gram-positive cocci.

### Claim 36 (depends on 33)

The method of claim 33 wherein the host cell is a bacterium, the bacterium being a non-cariogenic Streptococcus mutans.

### Claim 37 (depends on 33)

The method of claim 33 wherein the composition is administered orally, intranasally, or mucosally.

### Claim 38 (depends on 26)

A method for eliciting opsonic antibodies to at least one group A streptococci serotype without eliciting cross-reactive antibodies to mammalian tissue antigens, comprising administering to a patient in need thereof an effective amount of the composition according to claim 26.

### Claim 39 (depends on 27)

A method for eliciting opsonic antibodies to at least one group A streptococci serotype without eliciting cross-reactive antibodies to mammalian tissue antigens, comprising administering to a patient in need thereof an effective amount of the cocktail composition according to claim 27.

### Claim 40 (depends on 35)

The method for eliciting opsonic antibodies according to claim 35 wherein the composition is administered orally, intranasally, or mucosally.

### Claim 41 (depends on 39)

The method for eliciting opsonic antibodies according to claim 39 wherein the composition is administered orally, intranasally, or mucosally.
